Checking Measles Vaccine Protection in Young Children With Sickle Cell Disease
Checks whether measles vaccines protect infants and young children with sickle cell disease.
Plain-language title generated from the registry record
Registry title: Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Key facts
- Where
- Mwanza, TanzaniaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children with confirmed sickle cell disease who are due for measles vaccination within 3 months. It checks whether the vaccine gives them enough protection.
- Age
- From 6 months to 6 years.
- Sex
- All sexes can join.
- Disease stage
- Confirmed sickle cell disease.
- Earlier treatment
- Due for measles vaccination within 3 months, as set by national guidelines.
Main reasons for not taking part
- Known primary immunodeficiency syndrome that would prevent live virus vaccines
- Cancer that would prevent live virus vaccines
- AIDS that would prevent live virus vaccines
Read by machine on 9 November 2026.
Where in Tanzania
- Bugando Medical CentreMwanza, TanzaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Children's Hospital Medical Center, Cincinnati
- Trial code
- NCT07356050
- Record updated
- 21 January 2026
- Original description
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)Read full original descriptionShow less
Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Inclusion: Participants with confirmed Sickle Cell Disease; Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines; Willing and able to provide informed consent; Ability to comply with study related evaluations and follow-up visits.
Exclusion: Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.